Co-culture Lymphoid Tissue Equivalent for Predictive Immune Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for developing vaccines and drugs are inefficient due to high attrition rates and costly non-human animal models, which fail to accurately predict human immunological responses, limiting the translation of basic knowledge to clinical trials and innovation in vaccine development.
Innovation Solution
A cell culture system comprising T cells, B cells, and antigen-primed dendritic cells in a 1:1 ratio, mimicking a lymphoid tissue equivalent, is used to assess immune responses to antigens, allowing for in vitro testing of vaccines and pharmaceuticals, providing a more predictive and cost-effective alternative to animal models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-human animal models are used for vaccine and drug testing, then pre-clinical safety assessment can be performed, but the costs are high and the predictive accuracy for human responses is poor
Solution Approach 1:
The patent creates an artificial immune system that copies the essential functional components of the human immune system (dendritic cells, T cells, B cells, and their interactions) in an in vitro setting. This cellular model system replicates human immune responses without requiring animal subjects, thereby improving predictive accuracy while reducing costs associated with animal model maintenance, housing, and ethical compliance
Solution Approach 2:
The patent introduces an intermediary cellular system that mediates between drug/vaccine testing and human response prediction. The artificial immune system acts as a bridge, translating pre-clinical testing needs into human-relevant data through controlled cellular interactions that mimic human immunology, eliminating the need for costly and less accurate animal models
2Reliability
If traditional animal models are used for immune response testing, then safety data can be obtained, but the translation to human immunology is limited
Solution Approach 1:
By copying human immune cellular components and their interactions in an in vitro system, the patent enables direct modeling of human immunological responses. This eliminates the translational gap inherent in animal models, as the system directly replicates human cellular mechanisms rather than requiring species extrapolation
Solution Approach 2:
The artificial immune system performs preliminary immune response assessment in vitro before animal or human trials. By conducting initial safety and efficacy evaluations using human-relevant cellular models, the system prepares comprehensive pre-clinical data in advance, reducing the time needed for subsequent testing phases
3Ease of manufacture
If small animal models are used for vaccine development, then initial safety testing can be performed, but the costs remain high and ethical concerns arise
Solution Approach 1:
The patent employs cultured human immune cells in vitro that can be generated, tested, and discarded in controlled laboratory settings. These cellular models are more economical than animal models, requiring only standard laboratory equipment and reagents rather than animal facilities, veterinary care, and ethical compliance infrastructure
Solution Approach 2:
The artificial immune system serves as an intermediary testing platform that simplifies pre-clinical evaluation. By mediating between drug candidates and human response prediction through controlled cellular assays, the system makes testing more accessible and easier to conduct while reducing costs associated with animal model maintenance and regulatory compliance
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to methods for preparing an artificial immune system. The artificial immune system comprises a cell culture comprising T cells, B cells and antigen-primed dendritic cells. The artificial immune system of the present invention can be used for in vitro testing of vaccines, adjuvants, immunotherapy candidates, cosmetics, drugs, biologics and other chemicals.